The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear.
First telomerase inhibitor to significantly improve transfusion independence in ESA-refractory MDS — now a frontline option before luspatercept failure.
Prospective cohort demonstrating that targeted anti-inflammatory therapy in high-risk CHIP carriers reduces progression to AML/MDS. Bridges genomics, inflammation, and prevention.
